RPL13 and cancer: The robust downregulation of RPL13 in all six cancer nodules (by −1.70×/−1.38×/−1.36× in “P”/”Q”/“M” vs. “Z” and by −2.15×/−1.30×/−1.50× in “A”/”B”/”C” vs. “N”) explains the reduced immune response in cancer.